← Leaderboards
Laura Ensign
Johns Hopkins University
$10,004,174
Attributed
$18,917,430
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,917,430 · 12
By mechanism
R01$14,608,803 · 9
U24$2,493,155 · 1
R44$1,512,726 · 1
T32$302,746 · 1
Top collaborators
- Irina Burd10 shared
- Justin S. Hanes10 shared
- Peter A Campochiaro6 shared
- Steven L. Salzberg4 shared
- Sezen Karakus3 shared
- Narutoshi Hibino2 shared
- Tung Heng Hsueh2 shared
- Jeremy Nathans1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Irina Burd$5,463,290
- Kannan Rangaramanujam$10,355,612
- Barbara Stauch Slusher$18,499,514
- Rupak Shivakoti$5,705,971
- Sabra L Klein$13,115,675
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseFormulationPharmaceutical PreparationsDrug Delivery SystemsPreventToxic EffectTissuesDrug KineticsInflammationPenetrationDesignMouse ModelAbsorptionIn VitroPropertyRattusMucous MembraneSafetyOryctolagus CuniculusBrainTechnologyCellsInnovationPreclinical Study
Grant awards (40)
Development of standardized resources for characterization of the resident ocular surface microbiome.$835,729
U24 · FY2025 · EY · contact PI
Nanomedicine approaches for prevention of inflammation-induced preterm birth$629,685
R01 · FY2025 · HD · contact PI
Nanomedicine-based approach for characterizing the epigenome in prevention of inflammation-induced preterm birth.$608,481
R01 · FY2025 · HD · contact PI
Topical drug delivery formulations for neuroprotection in glaucoma$537,385
R01 · FY2025 · EY · contact PI
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections$471,413
R01 · FY2025 · EY · contact PI
Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseases$371,191
R01 · FY2025 · EY · contact PI
Visual Science Training Program$302,746
T32 · FY2025 · EY
Pharmaceutical development of longer-lasting brimonidine eye drops$964,469
R44 · FY2024 · EY
Development of standardized resources for characterization of the resident ocular surface microbiome.$876,641
U24 · FY2024 · EY · contact PI
Nanomedicine approaches for prevention of inflammation-induced preterm birth$623,389
R01 · FY2024 · HD · contact PI
Nanomedicine-based approach for characterizing the epigenome in prevention of inflammation-induced preterm birth.$602,396
R01 · FY2024 · HD · contact PI
Topical drug delivery formulations for neuroprotection in glaucoma$539,249
R01 · FY2024 · EY · contact PI
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections$471,413
R01 · FY2024 · EY · contact PI
Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseases$436,695
R01 · FY2024 · EY · contact PI
Development of standardized resources for characterization of the resident ocular surface microbiome.$145,027
U24 · FY2024 · EY · contact PI
Development of standardized resources for characterization of the resident ocular surface microbiome.$635,758
U24 · FY2023 · EY · contact PI
Nanomedicine approaches for prevention of inflammation-induced preterm birth$629,685
R01 · FY2023 · HD · contact PI
Nanomedicine-based approach for characterizing the epigenome in prevention of inflammation-induced preterm birth.$624,419
R01 · FY2023 · HD · contact PI
Pharmaceutical development of longer-lasting brimonidine eye drops$548,257
R44 · FY2023 · EY
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections$471,414
R01 · FY2023 · EY · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$409,375
R01 · FY2023 · EY · contact PI
Nanomedicine approaches for prevention of inflammation-induced preterm birth$629,685
R01 · FY2022 · HD · contact PI
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections$471,413
R01 · FY2022 · EY · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$397,094
R01 · FY2022 · EY · contact PI
Novel drug-eluting sutures to prevent vascular graft anastomosis stenosis$310,420
R01 · FY2022 · HL
Nanomedicine approaches for prevention of inflammation-induced preterm birth$72,214
R01 · FY2022 · HD · contact PI
Nanomedicine approaches for prevention of inflammation-induced preterm birth$629,685
R01 · FY2021 · HD · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$397,093
R01 · FY2021 · EY · contact PI
Novel drug-eluting sutures to prevent vascular graft anastomosis stenosis$310,420
R01 · FY2021 · HL
Nanomedicine approaches for prevention of inflammation-induced preterm birth$72,214
R01 · FY2021 · HD · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$409,375
R01 · FY2020 · EY · contact PI
Sustained-release of novel neuroprotective agents for treatment of glaucoma$405,000
R01 · FY2020 · EY · contact PI
Sustained-release of novel neuroprotective agents for treatment of glaucoma$405,000
R01 · FY2019 · EY · contact PI
Mucus-Penetrating Nanoparticle Containing Enemas for Ulcerative Colitis$364,500
R01 · FY2019 · DK · contact PI
Sustained-release of novel neuroprotective agents for treatment of glaucoma$405,000
R01 · FY2018 · EY · contact PI
Mucus-Penetrating Nanoparticle Containing Enemas for Ulcerative Colitis$364,500
R01 · FY2018 · DK · contact PI
Sustained-release of novel neuroprotective agents for treatment of glaucoma$405,000
R01 · FY2017 · EY · contact PI
Mucus-Penetrating Nanoparticle Containing Enemas for Ulcerative Colitis$364,500
R01 · FY2017 · DK · contact PI
Sustained-release of novel neuroprotective agents for treatment of glaucoma$405,000
R01 · FY2016 · EY · contact PI
Mucus-Penetrating Nanoparticle Containing Enemas for Ulcerative Colitis$364,500
R01 · FY2016 · DK · contact PI